Cytomegalovirus infection in renal transplant recipients

Transplant Infectious Disease

Volumn 8, Issue 4, 2006, Pages 203-212

  Carstens, J ^a   Andersen, H K ^a   Spencer, E ^a   Madsen, M ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Acute rejection; Antiviral agents; CMV; Ganciclovir; Renal transplantation

Indexed keywords

CYCLOSPORIN; GANCICLOVIR; TSUKUBAENOLIDE;

ADULT; ALLOTRANSPLANTATION; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROPHYLAXIS;

ADULT; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 33751239739     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2006.00169.x     Document Type: Article

References (26)

1. HOKEBERG I, ERIKSSON BM, ZWEYGBERG-WIRGART B, TUFVESSON G, OLDING-STENKVIST E, GRILLNER L. Diagnostic markers and risk factors of cytomegalovirus infection and disease in renal allograft recipients. Scand J Infect Dis 1995: 27: 435-440.
2. SAGEDAL S, NORDAL KP, HARTMANN A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000: 70: 1166-1174.
3. MCLAUGHLIN K, WU C, FICK G, MUIRHEAD N, HOLLOMBY D, JEVNIKAR A. Cytomegalovirus seromismatching increases the risk of acute renal allograft rejection. Transplantation 2002: 6: 813-816.
4. SAGEDAL S, NORDAL KP, HARTMANN A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002: 2: 850-856.
5. LERUEZ-VILLE M, OUACHÉE M, DELARUE R, et al. Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma. J Clin Microbiol 2003: 41: 2040-2046.
6. ROLLAG H, SAGEDAL S, KRISTIANSEN I, et al. Cytomegalovirus DNA concentration in plasma predicts development of cytomegalovirus disease in kidney transplant recipients. Clin Microbiol Infect 2002: 8: 431-434.
7. LOPEZ-ROCAFORT L, BRENNAN DC. Current review of cytomegalovirus in renal transplantation. Minerva Urol Nefrol 2001: 53: 145-158.
8. COUCHOUD C, CUCHERAT M, HAUGH M, POUTEIL-NOBLE C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation. Transplantation 1998: 5: 641-647.
9. GOURISHANKAR S, WONG W, DORVAL M. Meta-analysis of prophylaxis of CMV disease in solid organ transplantation: is ganciclovir a superior agent to acyclovir. Transplant Proc 2001: 33: 1870-1872.
10. HIBBERD PL, TOLKOFF-RUBIN NE, CONTI D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med 1995: 123: 18-26.
11. LJUNGMAN P, GRIFFITHS P, PAYA C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002: 34: 1094-1097.
12. BEIN G, BITSCH A, HOYER J, et al. A longitudinal prospective study of cytomegalovirus pp65 antigenemia in renal transplant recipients. Transpl Int 1993: 6: 185-190.
13. SAGEDAL S, HARTMANN A, ROLLAG H. The impact of early cytomegalovirus infection and disease in renal transplant recipients. Clin Microbiol Infect 2005: 11: 518-530.
14. SPENCER ES, FJELDBORG O, ANDERSEN HK. Cytomegalovirus infection and kidney graft survival. Scand J Urol Nephrol Suppl 1981: 64 : 128-131.
15. AHMED J, VELARDE C, RAMOS M, et al. Outcome of low-dose ganciclovir for cytomegalovirus disease prophylaxis in renal-transplant recipients. Transplantation 2004: 15: 1689-1692.
16. MURRAY BM, SUBRAMANIAM S. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients. Transpl Infect Dis 2004: 6: 3-9.
17. AKALIN E, SEHGAL V, AMES S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003: 3: 731-735.
18. REISCHIG T, OPATRNY K JR, BOUDA M, TRESKA V, JINDRA P, SVECOVA M. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transpl Int 2002: 15: 615-622.
19. SCHNITZLER MA, LOWELL JA, HMIEL SP, et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching. J Am Soc Nephrol 2003: 14: 780-785.
20. AHSAN N, HOLMAN MJ, YANG HC. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Clin Transplant 1997: 11: 633-639.
21. RAZONABLE RR, RIVERO A, RODRIGUEZ A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001: 184: 1461-1464.
22. GEDDES CC, CHURCH CC, COLLIDGE T, et al. Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function. Nephrol Dial Transplant 2003: 18: 1891-1898.
23. DAS A. Cytomegalovirus infection in solid organ transplantation: economic implications. Pharmacoeconomics 2003: 21: 467-475.
24. YANG CW, KIM YO, KIM YS, et al. Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay. Am J Nephrol 1998: 18: 373-378.
25. CAINELLI F, VENTO S. Infections and solid organ transplant rejection: a cause-and-effect relationship? Lancet Infect Dis 2002: 2: 539-549.
26. TURGEON N, FISHMAN JA, DORAN M, et al. Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. Transpl Infect Dis 2000: 2: 2-10.